Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Kenai Therapeutics a biotechnology company leveraging induced pluripotent stem cell iPSC technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders today announced an 82 million Series A financing coled by Alaska Permanent Fund Corporation Cure Ventures and The Column Group with participation from Euclidean Capital and Saisei Ventures.
Ryne Biotechnology has received a $4m CLIN1 grant from the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001.